Cargando…
The delayed bloodstream clearance of Plasmodium falciparum parasites after M5717 treatment is attributable to the inability to modify their red blood cell hosts
M5717 is a promising antimalarial drug under development that acts against multiple stages of the life cycle of Plasmodium parasites by inhibiting the translation elongation factor 2 (PfeEF2), thereby preventing protein synthesis. The parasite clearance profile after drug treatment in preclinical st...
Autores principales: | Parkyn Schneider, Molly, Looker, Oliver, Rebelo, Maria, Khoury, David S., Dixon, Matthew W. A., Oeuvray, Claude, Crabb, Brendan S., McCarthy, James, Gilson, Paul R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340534/ https://www.ncbi.nlm.nih.gov/pubmed/37457953 http://dx.doi.org/10.3389/fcimb.2023.1211613 |
Ejemplares similares
-
Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models
por: Yin, Xiaoyan, et al.
Publicado: (2023) -
Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor
por: Rottmann, Matthias, et al.
Publicado: (2020) -
Translation of liver stage activity of M5717, a Plasmodium elongation factor 2 inhibitor: from bench to bedside
por: Khandelwal, Akash, et al.
Publicado: (2022) -
PTEX helps efficiently traffic haemoglobinases to the food vacuole in Plasmodium falciparum
por: Jonsdottir, Thorey K., et al.
Publicado: (2023) -
The Medicines for Malaria Venture Malaria Box contains inhibitors of protein secretion in Plasmodium falciparum blood stage parasites
por: Looker, Oliver, et al.
Publicado: (2022)